Home » More Hepatitis C Developments Driving Home
More Hepatitis C Developments Driving Home
Peregrine Pharmaceuticals is a year-end winner in small-cap biotech and emerging pharma based upon hepatitis-C Phase II trial data. The preliminary data shows that antiviral activity and a positive safety profile at both bavituximab doses were evaluated.
24/7 Wall St.
24/7 Wall St.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May